Portfolio company
Hawkhill Therapeutics
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops oral small molecule therapies for obesity and metabolic health to preserve muscle mass for the biotechnology and pharmaceutical sectors.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Ousia Pharma
This biotechnology company develops peptide-drug conjugates to treat obesity and cardiometabolic diseases for patients requiring improved metabolic health and weight regulation.
Tanai Therapeutics
This company develops oral small molecule therapeutics targeting energy expenditure pathways to treat obesity and cardiometabolic diseases for patients.
Ambrosia Biosciences
This drug discovery company develops orally delivered small-molecule therapies for obesity and metabolic disorders for patients requiring alternatives to injectable treatments.
Kailera
This biopharmaceutical company develops injectable and oral therapies for the treatment of obesity and related metabolic conditions.
Fable Therapeutics
The company develops protein-engineered biologics using machine learning to treat patients with obesity and metabolic diseases.
Alveus Therapeutics
This clinical-stage biotechnology company develops next-generation therapies for obesity and metabolic diseases to provide sustained weight loss for patients.
Carmot Therapeutics
This biotechnology company develops drug therapies to treat metabolic diseases, such as obesity and diabetes, for patients with these conditions.
Moonwalk Therapeutics
This biotechnology company develops epigenetic and RNA interference medicines to treat obesity and cardiometabolic diseases for patients.
